UTI Shorts Build Into November Earnings With Analyst Covering Fire

Universal Technical Institute heads into its November 18 earnings report with a striking split: short sellers have been quietly adding to positions all month while the stock has staged a near-8% weekly recovery, and the one analyst who moved this week cut his target but kept a Buy.

The short interest story is the clearest structural tension here. Shorts have grown 31% over the past month, bringing the position to 13.1% of free float, roughly 7.1 million shares. That is a meaningful and growing bet against the stock. The week's build was modest, around 4.7%, but the monthly trend is hard to dismiss. What keeps this from looking like a powder keg is the lending market. Availability sits at 421%, meaning there are more than four shares available to borrow for every one already shorted. That is ample supply, well above the 52-week tightest reading of 218%, and borrow cost is a low 0.50%. Shorts face no squeeze mechanics at these levels. The ORTEX short score has been drifting higher all month and reached 59.1 on Tuesday, though it has pulled back from a recent peak above 60 in mid-October.

Options positioning has tilted slightly more cautious in recent weeks but is nowhere near extreme. The put/call ratio has climbed to 0.50, about one standard deviation above its 20-day average of 0.44. It is a gentle hedge rather than a fear signal. The 52-week high on PCR was 2.76, so options traders are nowhere near their most defensive posture. The pattern in PCR is readable: through September the ratio drifted lower as the stock fell, then popped sharply in mid-October as the stock stabilised and began recovering. At current levels, hedging has ticked up but remains measured.

The Street is unanimously bullish and consistently cutting targets, which is itself a tension worth naming. B. Riley's analyst trimmed his target this morning from $48 to $45, keeping a Buy rating. That follows Truist cutting from $47 to $38 in August after the last print. Rosenblatt and Barrington Research have both held Buy and Outperform respectively for months. The mean target across the group is $38.83 against a current price of $22.15, implying roughly 75% theoretical upside. The bull case rests on structural labor-market tailwinds, data-center-driven trades demand, and the view that near-term margin pain from campus expansion is temporary. The bear case is more specific: high school enrollment was around 1,000 students short of plan in the September quarter despite leads rising 15%, pointing to a conversion problem, not a demand problem. Management also cut full-year revenue guidance to $893 million to $900 million and trimmed EBITDA guidance to $100 million to $103 million. Capex ran $85.4 million through the first nine months, and free cash flow was negative $17.9 million. The EV/EBITDA multiple has compressed sharply, dropping about 3.2 turns over the past 30 days to roughly 8.6x, which reflects how quickly the market has discounted the guidance cut.

The ownership picture adds an important footnote. Coliseum Capital Management, which filed a Schedule 13D and was therefore a registered activist holder, has largely exited. Its stake fell from 7.3% to 1.76% as of June 10, including a $124 million open-market sale at $41.40 in early June, well above current prices. That exit removed a known active voice from the register. BlackRock moved the other way, filing a fresh 13G/A yesterday disclosing a 14% stake, up from 12.9% previously, now the largest single holder with roughly 7.7 million shares. T. Rowe Price and State Street also added meaningfully in the most recent quarter. On the insider side, director Robert DeVincenzi has been a consistent open-market buyer, purchasing 1,000 shares in each of several tranches through August and September at prices ranging from $19.68 to $25.95. These are small-scale purchases against a CEO who sold nearly $3.9 million worth of stock at $41 in late June, but the director pattern is at least directionally supportive.

The key variable for November 18 is whether the conversion data for high school starts shows improvement. The stock has already priced in a lot of disappointment, down from above $40 in June to around $22, and the borrow market is loose enough that the short position is probably not a catalyst on its own. What matters is whether the enrollment funnel is a structural problem or a one-quarter recruiting disruption.